Shares of Regenxbio plunged after the Food and Drug Administration placed clinical holds on two drug development programs after a five-year-old participant in one study developed an intraventricular ...
The discovery of a tumor in a patient who received REGENXBIO’s gene therapy for Hurler syndrome prompted the FDA to place a hold on that program along with the company’s Hunter syndrome program, which ...
Dr. Mohana Rao Patibandla presenting the 51-case BrainPath-assisted parafascicular intraventricular tumor surgery series at NSI 2025. Certificate from NSICON 2025 recognizing Dr. Mohana Rao Patibandla ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results